Neurogenic Orthostatic Hypotension (nOH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Neurogenic Orthostatic Hypotension (nOH) Market Outlook

Thelansis’s “Neurogenic Orthostatic Hypotension (nOH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurogenic Orthostatic Hypotension treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neurogenic Orthostatic Hypotension (nOH) Overview

Neurogenic orthostatic hypotension (nOH) is a specific form of orthostatic hypotension characterized by impaired regulation of standing blood pressure due to autonomic dysfunction. Patients with nOH assume an upright position and commonly experience dizziness, visual disturbances, presyncope, and syncope symptoms. However, many patients present with more subtle complaints, including tiredness, impaired cognitive function, weakness, fatigue, leg buckling, visual blurring, and difficulty breathing upon standing. These symptoms tend to worsen in hot weather or during fever, after heavy meals, during prolonged standing, and early in the morning. Various factors influence orthostatic hypotension. Cross-sectional analysis indicates that age, drug effects, orthostatic stress in neurological disorders (particularly Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and autonomic neuropathies), as well as dehydration, deconditioning, and poor nutrition, contribute to the development of orthostatic hypotension in the elderly population. Two distinct patient groups with primary nOH have been identified, regardless of clinical diagnosis. Patients with evidence of cardiac noradrenergic denervation on neuroimaging demonstrate loss of noradrenergic innervation throughout the body, abnormalities in neurochemical responses to test drugs, and evidence of compensatory upregulation of adrenoceptors. On the other hand, patients with central neurodegeneration and intact cardiac noradrenergic innervation on neuroimaging exhibit neurochemical abnormalities suggesting a deficiency in central norepinephrine. They often exhibit high blood pressure (supine hypertension) that disrupts the narrow range of normal blood pressure. As a result, patients may display orthostatic hypotension and supine hypertension at different times.

• The prevalence of orthostatic hypotension increases with age and is commonly associated with neurodegenerative diseases such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.
• The estimate of OH-related hospitalization is 36 per 100,000 adults, and the OH hospitalization rate can be as high as 233 per 100,000 patients >75 years of age, with a median length of stay of 3 days and an overall in-hospital mortality rate of 0.9%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: